PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
0.4491
-0.0109 (-2.37%)
Aug 14, 2025, 11:24 AM - Market open
PAVmed Revenue
PAVmed had revenue of $8.00K in the quarter ending March 31, 2025, a decrease of -99.21%. This brings the company's revenue in the last twelve months to $1.99M, down -33.92% year-over-year. In the year 2024, PAVmed had annual revenue of $3.00M with 22.15% growth.
Revenue (ttm)
$1.99M
Revenue Growth
-33.92%
P/S Ratio
2.53
Revenue / Employee
$51,103
Employees
39
Market Cap
7.91M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PAVM News
- 3 hours ago - PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results - PRNewsWire
- 1 day ago - Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results - PRNewsWire
- 9 days ago - Lucid Diagnostics to Participate in Upcoming Investor Conferences - PRNewsWire
- 14 days ago - PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025 - PRNewsWire
- 15 days ago - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 - PRNewsWire
- 15 days ago - PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - PRNewsWire
- 4 weeks ago - MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test - PRNewsWire
- 7 weeks ago - PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing - PRNewsWire